Thymosin alpha-1 improved virological and biochemical response rates in anti-HBe positive chronic hepatitis B patients, a subgroup that is particularly difficult to treat with standard therapies.
Treatment-resistant subgroupThymosin alpha-1 achieved virological and biochemical responses in anti-HBe positive hepatitis B — a subtype that resists standard treatments
What the researchers found
Thymosin alpha-1 improved virological (HBV DNA clearance) and biochemical (ALT normalization) responses in anti-HBe positive chronic hepatitis B, a treatment-resistant subgroup.
Why it matters
Anti-HBe positive hepatitis B has few effective treatments. A peptide immunotherapy that achieves meaningful response rates in this difficult subgroup addresses a significant unmet clinical need.
How the study worked
Multicenter randomized controlled trial comparing thymosin alpha-1 to no treatment in anti-HBe, HBV-DNA-positive chronic hepatitis B patients. Six-month treatment course with follow-up monitoring of HBV DNA and liver enzymes.
What this study cannot tell us
Specific response rates and confidence intervals not detailed in abstract excerpt. Anti-HBe positive HBV is heterogeneous. Long-term durability of response not established in this study.
How to read the evidence
Moderate evidence from a multicenter RCT in a relevant and difficult-to-treat patient population.
When this study was published
Published in 2000. Thymosin alpha-1 is approved for hepatitis B treatment in some countries, often combined with other antivirals.
The bigger picture
Hepatitis B affects 300 million people worldwide. For the subset with anti-HBe positive disease, treatment options are limited. Thymosin alpha-1's immune-boosting approach offers a different mechanism from standard antivirals.
Questions still open
- Should thymosin alpha-1 be combined with nucleos(t)ide analogs for better HBV responses?
- What immune mechanisms mediate thymosin alpha-1's antiviral effect?
- Can thymosin alpha-1 achieve functional cure (HBsAg loss)?
Common questions
Can thymosin alpha-1 treat hepatitis B?
How does it work differently from antivirals?
Read the original research
A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
Digestive diseases and sciences, 45(4), 690-6
Citation
Zavaglia, C; Severini, R; Tinelli, C; Franzone, J S; Airoldi, A; Tempini, S; Bettale, G; Ideo, G. (2000). A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.. Digestive diseases and sciences, 45(4), 690-6.